Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
|
JUNIPER PHARMACEUTICALS INC (JNP)
|
Add to portfolio |
|
|
|
| Price: |
$11.50
| | Metrics |
| OS: |
11.3
|
M
| |
-1
|
% ROE
|
| Market cap: |
$130
|
M
| |
-12
|
% ROIC
|
|
Net cash:
|
$17.4
|
M
| |
$1.53
|
per share
|
|
EV:
|
$113
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($2.2)
|
M
| |
|
|
| EPS |
($0.05)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| Revenues | 50.0 | 54.6 | 38.3 | 33.4 | 27.6 | 25.8 | 43.1 | 45.7 |
| Revenue growth | -8.4% | 42.5% | 14.7% | 21.1% | 6.8% | -40.0% | -5.7% | 41.9% |
| Cost of goods sold | 29.0 | 24.3 | 21.4 | 17.7 | 13.3 | 12.8 | 11.7 | 9.0 |
| Gross profit | 21.0 | 30.3 | 16.9 | 15.7 | 14.3 | 13.0 | 31.4 | 36.7 |
| Gross margin | 42.1% | 55.5% | 44.1% | 47.0% | 52.0% | 50.5% | 72.8% | 80.3% |
| Sales and marketing | 1.9 | 1.3 | 1.2 | 1.7 | 0.4 | | 0.1 | 9.7 |
| Research and development | 6.9 | 9.7 | 7.0 | 0.7 | | 0.8 | 2.8 | 8.6 |
| General and administrative | 15.4 | 14.1 | 10.5 | 8.6 | 8.0 | 9.5 | 8.1 | 14.7 |
| EBITA | -2.8 | 5.7 | -1.5 | 5.4 | 4.2 | 2.8 | 20.4 | 3.7 |
| EBITA margin | -5.6% | 10.4% | -3.8% | 16.3% | 15.3% | 10.9% | 47.4% | 8.1% |
| Amortization of intangibles | 0.3 | 0.4 | 0.4 | 0.7 | | | | 2.5 |
| EBIT | -3.1 | 5.3 | -1.9 | 4.7 | 4.2 | 2.8 | 20.4 | 1.2 |
| EBIT margin | -6.2% | 9.7% | -4.9% | 14.2% | 15.3% | 10.9% | 47.4% | 2.6% |
| Pre-tax income | -2.2 | 6.0 | -1.5 | 5.3 | 5.1 | 9.9 | 20.6 | -22.3 |
| Income taxes | -0.2 | 0.1 | 0.0 | 0.7 | 0.3 | 0.0 | 0.0 | 0.0 |
| Tax rate | 8.3% | 1.5% | | 12.3% | 6.7% | 0.0% | 0.2% | 0.0% |
| Net income | -1.6 | 5.9 | -1.5 | 4.7 | 4.7 | 9.9 | 20.5 | -21.8 |
| Net margin | -3.2% | 10.9% | -4.0% | 13.9% | 17.2% | 38.4% | 47.7% | -47.8% |
| |
| Diluted EPS | ($0.15) | $0.54 | ($0.14) | $0.42 | $0.42 | $0.90 | $1.77 | ($0.30) |
| Shares outstanding (diluted) | 10.8 | 10.9 | 10.8 | 11.0 | 11.3 | 11.1 | 11.6 | 73.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|